Accordingly, the results of the anti-PD-1 antibody + regorafenib + chidamide-k30 triple combination were likely attributed to the altering of tumor-infiltrating immune cells, increasing CD8+ T-cells and decreasing immune-suppressive PMN-MDSCs and TAMs in tumors. This evidence concerns the gene CD8A and neoplasm.